Use of substances (e.g. nucleic acids, proteins and peptides), which restrain/reduce the expression and/or activity of protein kinase C-epsilon for the treatment/prevention of e.g. circulatory and vascular diseases

摘要

Use of substances (I) which restrain or reduce the expression and/or activity of protein kinase C-epsilon (PKCeta ) for the treatment and/or prevention of e.g. heart circulation diseases, vascular diseases, kidney diseases, disorders of metabolic dysfunction, cardiovascular complications in patients, diseases caused due to continuous or temporary oxygen deficiency, acute and/or chronic repulsion after transplantation, is new. Use of substances (I) which restrain or reduce the expression and/or activity of protein kinase C-epsilon (PKCeta ) for the treatment and/or prevention of heart circulation diseases, vascular diseases, kidney diseases, disorders of metabolic dysfunction e.g. latent diabetes, cardiovascular complications in patients with hypertonia, hypercholesteremia, diabetes mellitus, renal failure or restricted renal function with a glomerular filtration rate of less than 80 ml/minute, diseases or one or several and/or organ system conditions caused due to continuous or temporary oxygen deficiency, acute and/or chronic repulsion after organ transplantation, chronic transplantation dysfunction and/or transplant vasculopathy, is new. An independent claim is also included for use of (I) for modulating phosphorylation and/or activation of mitogen activated protein (MAP) kinase. ACTIVITY : Cardiant; Vasotropic; Cerebroprotective; Nephrotropic; Antidiabetic; Ophthalmological; Neuroprotective; Gastrointestinal-Gen; Cardiovascular-Gen; Antiinflammatory; Immunosuppressive; Dermatological; Antiulcer; Respiratory-Gen.; Hepatotropic; Antipsoriatic; Antiasthmatic; Apoptotic; Antiapoptotic. MECHANISM OF ACTION : Protein kinase C epsilon inhibitor; Mitogen activated protein kinase modulator; Tumor necrosis factor alpha inhibitor.